De Smet Dieter, Vanhee Merijn, Maes Brigitte, Swaerts Koen, De Jaeger Peter, Maelegheer Karel, Van Hoecke Frederik, Martens Geert Antoine
Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium.
Department of Clinical Biology, Jessa Hospital, Hasselt, Belgium.
Am J Clin Pathol. 2022 May 4;157(5):731-741. doi: 10.1093/ajcp/aqab186.
Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern associated with immune escape is important to safeguard vaccination efficacy. We describe the potential of delayed N gene amplification in the Allplex SARS-CoV-2 Assay (Seegene) for screening of the B.1.351 (20H/501.V2, variant of concern 2 [VOC.V2], South African SARS-CoV-2 variant) lineage.
In a study cohort of 397 consecutive polymerase chain reaction-positive samples genotyped by whole-genome sequencing, amplification curves of E/N/S-RdRP targets indicated delayedN vs E gene amplification characteristic of B.1.351. Logistic regression was used to calculate a VOC.V2 probability score that was evaluated as a separate screening test in an independent validation cohort vs sequencing.
B.1.351 showed a proportionally delayed amplification of the N vs E gene. In logistic regression, only N and E gene cycle thresholds independently contributed to B.1.351 prediction, allowing calculation of a VOC.V2 probability score with an area under the curve of 0.94. At an optimal dichotomous cutoff point of 0.12, the VOC.V2 probability score achieved 98.7% sensitivity at 79.9% specificity, resulting in a negative predictive value (NPV) of 99.6% and a positive predictive value of 54.6%. The probability of B.1.351 increased with an increasing VOC.V2 probability score, achieving a likelihood ratio of 12.01 above 0.5. A near-maximal NPV was confirmed in 153 consecutive validation samples.
Delayed N vs E gene amplification in the Allplex SARS-CoV-2 Assay can be used for fast and highly sensitive screening of B.1.351.
检测与免疫逃逸相关的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株对于保障疫苗接种效果至关重要。我们描述了Allplex SARS-CoV-2检测法(Seegene公司)中N基因扩增延迟在筛查B.1.351(20H/501.V2,变异株2 [VOC.V2],南非SARS-CoV-2变异株)谱系方面的潜力。
在一个由397份通过全基因组测序进行基因分型的连续聚合酶链反应阳性样本组成研究队列中,E/N/S-RdRP靶点的扩增曲线显示出B.1.351特有的N基因与E基因扩增延迟。采用逻辑回归计算VOC.V2概率评分,并在一个独立验证队列中与测序结果进行比较,将其作为一项单独的筛查试验进行评估。
B.1.351显示出N基因相对于E基因成比例的扩增延迟。在逻辑回归中,只有N基因和E基因的循环阈值独立地对B.1.351的预测有贡献,从而能够计算出曲线下面积为0.94的VOC.V2概率评分。在最佳二分截止点为0.12时,VOC.V2概率评分在特异性为79.9%时灵敏度达到98.7%,阴性预测值(NPV)为99.6%,阳性预测值为54.6%。B.1.351的概率随着VOC.V2概率评分的增加而增加,在评分高于0.5时似然比达到12.01。在153份连续的验证样本中证实了接近最大的NPV。
Allplex SARS-CoV-2检测法中N基因相对于E基因的扩增延迟可用于B.1.351的快速且高灵敏度筛查。